Kane, JM, Sharif, ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry. 2008; 69(Suppl 1): 18–31.
Hawley, CJ, Gale, TM, Sivakumaran, T, etal. Excessive daytime sleepiness in psychiatric disorders: prevalence, correlates and clinical significance. Psychiatry Res. 2010; 175(1–2): 138–141.
Colten, HR, Altevogt, BM, eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington, DC: National Academy of Sciences. http://www.ncbi.nlm.nih.gov/books/NBK19958. Accessed July 16, 2012.
Harvey, PD, Hassman, H, Mao, L, etal. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar 1 disorder: a randomized, double-blind, crossover study. J Clin Psychiatry. 2007; 68(8): 1186–1194.
Johns, MA. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991; 14(6): 540–545.
Johns, MW. Epworth Sleepiness Scale (ESS). In Rush Jr AJ, First MB, Blacker D, Eds. Handbook of Psychiatric Measures, 2nd ed.
Washington, DC: American Psychiatric Publishing; 2008.
Fleischhacker, WW, Heikkinen, ME, Olié, JP, etal. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010; 13(8): 1115–1125.
Loebel, A, Cucchiaro, J, Sarma, K, etal. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Res. 2013; 145(1–3): 101–109.
Sheehan, DV, Lecrubier, Y, Sheehan, KH, etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structural diagnostic psychiatric interview for DSM-IV and ICD-10 1996. J Clin Psychiatry. 1998; 59(Suppl 20): 22–23.
Baldwin, CM, Scott, LJ. Quetiapine extended release: in schizophrenia. CNS Drugs. 2009; 23(3): 261–269.
Zhornitsky, S, Potkin, S, Moteshafi, H, etal. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011; 26(4): 183–189.
Chervin, RD. The multiple sleep latency test and Epworth Sleepiness Scale in the assessment of daytime sleepiness. J Sleep Res. 2000; 9(4): 397–400.
Lohr, JB, Liu, L, Caligiuri, MP, etal. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2013; 150: 289–296.
Kay, SR, Fiszbein, A, Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
Lindenmayer, JP, Brown, E, Baker, RW, etal. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophrenia Res. 2004; 68(2–3): 331–337.
Pietrzak, RH, Olver, J, Norman, T, etal. A comparison of the CogState schizophrenia battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol. 2009; 31(7): 848–859.
Mausbach, BT, Harvey, PD, Goldman, SR, etal. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr Bull. 2007; 33(6): 1364–1372.
Mackinnon, DP, Fairchild, AJ, Matthew, SF. Mediation analysis. Annu Rev Psychol. 2007; 58: 593–614.
Kraemer, HC, Wilson, GT, Fairburn, CG, etal. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry. 2002; 59(10): 877–883.
Harvey, PD, Velligan, DI. International assessment of functional skills in people with schizophrenia: innovations in clinical neuroscience. Innov Clin Neurosci. 2011; 8(1): 15–18.
Harvey, PD, Siu, CO, Hsu, J, etal. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013; 23(11): 1373–1382.
Riesenberg, RA, Baldytcheva, I, Datto, C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-released during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clin Ther. 2012; 34(11): 2202–2211.
Witek, TJ Jr, Canestrari, DA, Miller, RD, etal. Characterization of daytime sleepiness and psychomotor performance following H1 receptor antagonists. Ann Allergy Asthma Immunol. 1995; 74(5): 419–426.
Ishibashi, T, Horisawa, T, Tokuda, K, etal. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-HT7 and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010; 334(1): 171–181.
Leucht, S, Cipriani, A, Spineli, L, etal. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
Horiguchi, M, Huang, M, Meltzer, HY. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther. 2011; 338(2): 605–614.
Guilleminault, C, Brooks, SN. Excessive daytime sleepiness: a challenge for the practising neurologist. Brain. 2001; 124(Pt 8): 1482–1491.
Rosenheck, RA. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anti-cholinergics as a comparator. Psychiatr Serv. 2005; 56(1): 85–92.
Leucht, S, Corves, C, Arbter, D, etal. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
Lancet. 2009; 373(9657): 31–41.